BIOMAT Database Logo BIOMAT Database Logo

[Results of combination chemotherapy with etoposide, ifosfamide, peplomycin for advanced prostatic cancer]. 1993

T Ushiyama, and H Ihara, and Y Kurita, and S Kageyama, and D Ueda, and S Mugiya, and Y Yamaguchi, and M Nakano, and K Suzuki, and K Kawabe
Department of Urology, Hamamatsu University School of Medicine.

Between August, 1986 and August, 1992, 16 combination chemotherapies with etoposide (100 mg/body, day 1-5), ifosfamide (50 mg/kg, day 1, 3, 5), peplomycin (5 mg/body, day 1-5) were performed on 13 patients with endocrine therapy-relapsed advanced prostatic cancer. Seven trials were performed on 5 patients who received DESP (diethylstilbestrol diphosphate) (500 mg/body, day 1-5) with the chemotherapy. In 9 trials performed on 9 patients who did not receive DESP, there was no response case. In 7 trials with DESP, one trial had a partial response (PR) (14%) and 4 remained objectively stable (stable) (57%). As to adverse effects, myelosuppression was observed in all trials but there was no lethal toxicity. The one-year survival rate of these patients treated with the chemotherapy alone and combined DESP were both about 20%. Therefore we should find a more effective treatment for endocrine relapsed prostatic cancer.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009919 Orchiectomy The surgical removal of one or both testicles. Castration, Male,Orchidectomy,Castrations, Male,Male Castration,Male Castrations,Orchidectomies,Orchiectomies
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D004054 Diethylstilbestrol A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) Stilbestrol,Agostilben,Apstil,Diethylstilbestrol, (Z)-Isomer,Diethylstilbestrol, Disodium Salt,Distilbène,Stilbene Estrogen,Tampovagan,Estrogen, Stilbene
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Ushiyama, and H Ihara, and Y Kurita, and S Kageyama, and D Ueda, and S Mugiya, and Y Yamaguchi, and M Nakano, and K Suzuki, and K Kawabe
[Combination chemotherapy of vincristine, ifosfamide and peplomycin in patients with reactivated prostatic cancer].
February 1986, Hinyokika kiyo. Acta urologica Japonica,
T Ushiyama, and H Ihara, and Y Kurita, and S Kageyama, and D Ueda, and S Mugiya, and Y Yamaguchi, and M Nakano, and K Suzuki, and K Kawabe
Chemotherapy of advanced prostatic cancer with peplomycin.
January 1981, The Prostate. Supplement,
T Ushiyama, and H Ihara, and Y Kurita, and S Kageyama, and D Ueda, and S Mugiya, and Y Yamaguchi, and M Nakano, and K Suzuki, and K Kawabe
Combination chemotherapy with 254-S, ifosfamide, and peplomycin for advanced or recurrent cervical cancer.
May 1993, Cancer,
T Ushiyama, and H Ihara, and Y Kurita, and S Kageyama, and D Ueda, and S Mugiya, and Y Yamaguchi, and M Nakano, and K Suzuki, and K Kawabe
[Combination chemotherapy with 254-S, ifosfamide and peplomycin for advanced or recurrent cervical cancer].
March 1992, Nihon Sanka Fujinka Gakkai zasshi,
T Ushiyama, and H Ihara, and Y Kurita, and S Kageyama, and D Ueda, and S Mugiya, and Y Yamaguchi, and M Nakano, and K Suzuki, and K Kawabe
[Combination chemotherapy of ifosfamide and etoposide for advanced neuroblastoma].
December 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
T Ushiyama, and H Ihara, and Y Kurita, and S Kageyama, and D Ueda, and S Mugiya, and Y Yamaguchi, and M Nakano, and K Suzuki, and K Kawabe
[Combination chemotherapy with ifosfamide (or cyclophosphamide), adriamycin, cis-platinum and peplomycin (IAPP) for hormonally resistant metastatic prostatic cancer].
December 1991, Hinyokika kiyo. Acta urologica Japonica,
T Ushiyama, and H Ihara, and Y Kurita, and S Kageyama, and D Ueda, and S Mugiya, and Y Yamaguchi, and M Nakano, and K Suzuki, and K Kawabe
[A trial of combination chemotherapy. Cis-platinum, peplomycin and adriamycin for advanced prostatic cancer].
August 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
T Ushiyama, and H Ihara, and Y Kurita, and S Kageyama, and D Ueda, and S Mugiya, and Y Yamaguchi, and M Nakano, and K Suzuki, and K Kawabe
Treatment of advanced refractory sarcomas with ifosfamide and etoposide combination chemotherapy.
January 1998, Cancer investigation,
T Ushiyama, and H Ihara, and Y Kurita, and S Kageyama, and D Ueda, and S Mugiya, and Y Yamaguchi, and M Nakano, and K Suzuki, and K Kawabe
[Low dose COMPE. Cisplatin, vincristine, methotrexate, peplomycin, etoposide chemotherapy for advanced testicular cancer].
April 1994, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
T Ushiyama, and H Ihara, and Y Kurita, and S Kageyama, and D Ueda, and S Mugiya, and Y Yamaguchi, and M Nakano, and K Suzuki, and K Kawabe
Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma.
March 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
Copied contents to your clipboard!